- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02766816
A Clinical Study Comparing Safety and Immunogenicity of bOPV of Bilthoven Biologicals
A Phase III, Observer Blind, Active Controlled, Randomized, Clinical Study Comparing Safety and Immunogenicity of BBio Bivalent Oral Polio Vaccine With a Licensed Bivalent Oral Polio Vaccine
Study Overview
Status
Conditions
Detailed Description
Bilthoven Biologicals has developed a new bivalent OPV containing WHO approved Sabin strains of poliovirus type 1 and type 3. This phase III study will be conducted in two parts:
Part 1 - 40 children of 60 to 83 months of age will be given single dose of BBio bOPV or licensed bOPV in 1:1 ratio. Primary objective is to assess safety of BBio bOPV.
Part 2 - A total of 1080 infants of 42 to 56 days of age will be randomized to receive three doses of either BBio bOPV from one of the three lots or a licensed bOPV in 1:1:1:1 ratio as primary immunization series at 6, 10 and 14 weeks of age.
Primary objective of this study is to assess non-inferiority of bOPV manufactured by BBio to that of licensed bOPV in terms of seroconversion. This study also will assess lot-to-lot consistency among three lots of BBio bOPV.
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
Chittagong Division
-
Matlab South, Chandpur District, Chittagong Division, Bangladesh, 3640
- Matlab Hospital Research Centre, International Center for Diarrheal Disease Research, Matlab
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Normal healthy children of both sexes of age 5 to 6 years (60-83 months) at the time of vaccination and who have received at least 3 doses of trivalent oral polio vaccine (tOPV) based upon documentation (Study Part 1).
- Normal healthy infants of both sexes of age 6-8 weeks (42-56 days) at the time of the first vaccination and have not received oral polio vaccine (OPV) previously based upon documentation (Study Part 2).
- Parents/legal guardians of participants willing to give written informed consent and willing to comply with study protocol.
- Free of obvious health problems as established by medical history and screening evaluation including clinical examination.
- Resident of study area.
Exclusion Criteria:
- Participation in another clinical trial in the 4 weeks preceding the (first) trial vaccination or planned participation in another clinical trial during the present trial period.
- A diagnosis or suspicion of congenital or acquired immunodeficiency disorder, malignancy, receiving immunosuppressive therapy such as systemic corticosteroids therapy for a period of ≥ 1 week either in the participant or in an immediate family member.
- A diagnosis or suspicion of bleeding disorder that would contraindicate collection of blood by venipuncture.
- Acute or persistent diarrhea (defined as diarrhea that lasts 14 days or longer), infection or illness at the time of enrollment (6-8 weeks of age) that would require participant's admission to a hospital or would contraindicate provision of OPV.
- Acute vomiting and intolerance to liquids within 24 hours before the enrollment visit.
- Infants from multiple births (i.e. twins).
- History of allergy or systemic hypersensitivity to any of the vaccine components or history of a life-threatening reaction to the study vaccines or a vaccine containing the same substances.
- Chronic illness at a stage that could interfere with trial conduct or completion.
- Planned administration/ administration of a vaccine not foreseen by the study protocol during the study period with the exception of routine Expanded Program on Immunization (EPI) program vaccines including pneumococcal vaccine, and rotavirus vaccine (Polio vaccines are not allowed during the study period).
- Blood or blood-derived products received in the past.
- Any vaccination one week preceding the trial vaccination.
- Presence of significant malnutrition (< -3 standard deviation [SD] weight for length) or acute or chronic, clinically significant pulmonary, endocrine, autoimmune, cardiovascular, metabolic, hepatic or renal functional abnormality, as determined by medical history, and physical examination, which in the opinion of the investigator, might interfere with the study objectives
- History of any neurological disorder or history of seizure (febrile or afebrile), or encephalopathy, encephalitis, hypotonic-hyporesponsive episode.
- Febrile illness or acute illness on the day of inclusion is temporary exclusion criterion.
- Participant with any other condition, which, in the opinion of the investigator would jeopardize the safety or rights of the participant participating in the study or making it unlikely the participant, could complete the protocol.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: PREVENTION
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: DOUBLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Part 1 Study - BBio bOPV
|
A single dose of 2 drops (0.1 ml) orally of BBio bOPV to 20 children 60 to 83 months of age.
|
ACTIVE_COMPARATOR: Part 1 Study - Licensed bOPV
|
A single dose of 2 drops (0.1 ml) orally of a licensed bOPV to 20 children 60 to 83 months of age.
|
EXPERIMENTAL: Part 2 Study - BBio bOPV Lot 1
|
Three doses of 2 drops (0.1 ml) orally of BBio bOPV Lot 1 to 270 infants at 6-8, 10-12 and 14-16 weeks of age.
|
EXPERIMENTAL: Part 2 Study - BBio bOPV Lot 2
|
Three doses of 2 drops (0.1 ml) orally of BBio bOPV Lot 2 to 270 infants at 6-8, 10-12 and 14-16 weeks of age.
|
EXPERIMENTAL: Part 2 Study - BBio bOPV Lot 3
|
Three doses of 2 drops (0.1 ml) orally of BBio bOPV Lot 3 to 270 infants at 6-8, 10-12 and 14-16 weeks of age.
|
ACTIVE_COMPARATOR: Part 2 Study - Licensed bOPV
|
Three doses of 2 drops (0.1 ml) orally of a licensed bOPV to 270 infants at 6-8, 10-12 and 14-16 weeks of age.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Part 1 study: Frequency of adverse events (AEs)
Time Frame: 4 Days
|
Safety of single dose of BBio bOPV will be assessed at 4 days after vaccination.
|
4 Days
|
Part 2 study: Percentage of seroconversion to poliovirus type 1 and type 3
Time Frame: one month after dose 3
|
Percentage of seroconversion to poliovirus type 1 and type 3 one month after administration of third dose of the BBio bOPV to that of control group bOPV to assess non-inferiority of BBio bOPV to that of a licensed bOPV.
|
one month after dose 3
|
Part 1 study: Frequency of AEs and serious AEs (SAEs)
Time Frame: 28 days
|
Safety of single dose of BBio bOPV will be assessed at 28 days after vaccination.
|
28 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Part 1 study: Percentage of seroprotection to poliovirus type 1 and type 3
Time Frame: one month
|
Percentage of seroprotection to poliovirus type 1 and type 3 one month after administration of single dose of the BBio bOPV to that of control group.
|
one month
|
Part 1 study: Geometric mean titers (GMTs) of poliovirus neutralizing antibody (PVNA) to poliovirus type 1 and type 3
Time Frame: one month
|
GMTs of PVNA to poliovirus type 1 and type 3 at one month after administration of single dose of the BBio bOPV.
|
one month
|
Part 2 study: GMTs of serum PVNA for the three lots of BBio bOPV
Time Frame: one month after dose 3
|
Serum PVNA concentrations expressed as GMTs for the BBio bOPV to assess equivalence in manufacturing consistency among three current Good Manufacturing Practices (cGMP) lots of the BBio bOPV.
|
one month after dose 3
|
Part 2 study: GMTs of PVNA to poliovirus type 1 and type 3
Time Frame: one month after dose 3
|
Comparison of GMTs of PVNA to poliovirus type 1 and type 3 at one month after administration of third dose of the BBio bOPV to that of control group bOPV.
|
one month after dose 3
|
Part 2 study: Percentage of seroprotection to poliovirus type 1 and type 3
Time Frame: one month after dose 3
|
Percentage of seroprotection to poliovirus type 1 and type 3 one month after administration of third dose of the BBio bOPV to that of control group bOPV.
|
one month after dose 3
|
Part 2 study: Frequency of adverse events within 4 days following the administration of each dose of vaccine
Time Frame: 4 days after each dose of vaccine
|
Frequency of adverse events within 4 days following the administration of each dose of vaccine
|
4 days after each dose of vaccine
|
Part 2 study: Frequency of adverse events and serious adverse events
Time Frame: 84 days
|
84 days
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: K Zaman, MBBS, MPH, International Center for Diarrheal Disease Research
Publications and helpful links
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- OPV-03/PR-15106
- PR-15106 (OTHER: icddr,b)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Immune Response to Oral Polio Vaccine
-
PATHChristian Medical College, Vellore, India; Ministry of Science and Technology...CompletedImmunity to Oral Rotavirus Vaccine | Immunity to Oral Polio Vaccine | Shedding of Oral Rotavirus VaccineIndia
-
Serum Institute of India Pvt. Ltd.PATHCompletedImmune Response to MMR VaccineIndia
-
Aga Khan UniversityWorld Health OrganizationUnknown
-
Serum Institute of India Pvt. Ltd.PATHTerminatedImmune Response to DTP-HB-Hib VaccineIndia
-
Touro University, CaliforniaSanofiCompletedPatient Response to Fluzone ID VaccineUnited States
-
University of Colorado, DenverRecruitingKidney Transplant Recipient Response to Shingrix VaccineUnited States
-
Chulalongkorn UniversityBioNet-Asia; Chula Clinical Research Center (Chula CRC), Faculty of Medicine... and other collaboratorsRecruitingSafety of 25 ug of ChulaCov19-BNA159 mRNA Vaccine | Tolerability of 25 ug of ChulaCov19-BNA159 mRNA Vaccine | Immune Response of 25 ug of ChulaCov19-BNA159 mRNA Vaccine | Safety of 50 ug of ChulaCov19-BNA159 mRNA Vaccine | Tolerability of 50 ug of ChulaCov19-BNA159 mRNA Vaccine | Immune Response... and other conditionsThailand
-
Bandim Health ProjectStatens Serum Institut; Research Center for Vitamins and VaccinesUnknownMortality | Children | Oral Polio Vaccine | Morbidity | Measles Vaccination | Non-specific/Heterologous Effects of VaccinesGuinea-Bissau
-
National Institute of Allergy and Infectious Diseases...Emergent BioSolutionsCompletedVaccine ResponseUnited States
-
University of OxfordCompletedImmune Response | BCG Infection | Reaction - VaccineUnited Kingdom
Clinical Trials on Part 1 study - BBio bOPV
-
Institute of Medical Biology, Chinese Academy of...Guangxi Center for Disease Control and PreventionCompleted
-
U.S. Army Medical Research and Development CommandNational Institutes of Health (NIH); Mahidol UniversityCompletedDiarrhea | Dysentery | ShigellaThailand
-
Novartis PharmaceuticalsCompletedHematological MalignanciesGermany, Switzerland, France
-
Société des Produits Nestlé (SPN)CompletedExocrine Pancreatic InsufficiencyAustralia, New Zealand
-
Novartis PharmaceuticalsCompletedPrimary Biliary CholangitisUnited States, Germany, Russian Federation, Canada, United Kingdom, Poland
-
PfizerCompletedRheumatoid Arthritis | Healthy VolunteersUnited States
-
Ichnos Sciences SAGlenmark Pharmaceuticals S.A.CompletedModerate to Severe Atopic DermatitisUnited States, Canada, Czechia, Germany, Poland
-
Chiesi Farmaceutici S.p.A.CompletedCystic Fibrosis | Non-Cystic Fibrosis BronchiectasisBelgium
-
Janssen Research & Development, LLCCompletedHealthy | Asthma | Atopic DermatitisGermany, Belgium
-
Janssen Research & Development, LLCPharmacyclics LLC.CompletedCD20-positive B-cell Non-Hodgkin LymphomaUnited States, France